Lisinopril vs Enalapril: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Lisinopril directly inhibits angiotensin-converting enzyme (ACE), a zinc-dependent metalloenzyme that requires zinc at its active site to function. By occupying the active site, lisinopril displaces zinc and increases urinary zinc excretion by 2–3 fold above baseline. CTD documents gene interactions affecting ACE pathway genes, bradykinin metabolism, and mineral transport proteins. Unlike enalapril, lisinopril is not a prodrug — it requires no hepatic activation, meaning its zinc-displacing activity begins immediately upon absorption.
Lisinopril has only 25% oral bioavailability but a long 30-hour half-life, allowing once-daily dosing with sustained ACE inhibition — and sustained zinc excretion — throughout the full 24-hour period.
- ✓No hepatic activation required — works immediately and safe in liver impairment
- ✓30-hour half-life provides true 24-hour blood pressure coverage with once-daily dosing
- ✓FAERS documents 181,237 reports — the most extensive real-world safety dataset among ACE inhibitors
- ✓Only depletes one nutrient (zinc) — the lightest depletion burden of any major antihypertensive class
- ✗Low 25% bioavailability means 75% of each dose is never absorbed — requiring higher prescribed doses
- ✗30-hour half-life means continuous zinc excretion with no overnight recovery window
- ✗Class-effect ACE inhibitor cough affects 5–20% of patients — often requiring switch to ARB
- ✗Cannot be used in pregnancy — teratogenic effects are a class contraindication
Patients with hypertension or heart failure who need once-daily dosing simplicity, have normal to mild liver impairment, and can supplement zinc consistently.
Enalapril is a prodrug that requires hepatic conversion to its active form, enalaprilat, which then inhibits the same zinc-dependent ACE enzyme as lisinopril. The zinc displacement and increased urinary excretion mechanism is identical. CTD documents gene interactions affecting the renin-angiotensin system and zinc homeostasis pathways. The prodrug activation step means patients with liver dysfunction may have impaired conversion and unpredictable ACE inhibition — and unpredictable zinc depletion patterns.
Enalapril reaches 40% bioavailability with a 12.5-hour half-life for the active metabolite enalaprilat, typically requiring twice-daily dosing for adequate 24-hour blood pressure control.
- ✓Higher bioavailability (40% vs 25%) means lower prescribed doses needed for equivalent effect
- ✓Shorter 12.5-hour half-life may allow partial zinc recovery between twice-daily doses
- ✓Extensive landmark trial data including CONSENSUS and SOLVD for heart failure outcomes
- ✓Available in IV form (enalaprilat) for hypertensive emergencies — lisinopril has no IV option
- ✗Prodrug requires liver activation — impaired in hepatic dysfunction, creating unpredictable response
- ✗FAERS logs 21,226 reports with a higher death-associated rate than lisinopril — partly reflecting sicker HF populations
- ✗Twice-daily dosing reduces adherence compared to lisinopril's once-daily convenience
- ✗Same ACE inhibitor cough (5–20%) and pregnancy contraindication as all ACE inhibitors
Heart failure patients (backed by CONSENSUS and SOLVD landmark trials), those needing IV ACE inhibition access, or patients who benefit from twice-daily dosing's potential for intermittent zinc recovery.
Feature Comparison
| Feature | Lisinopril | Enalapril |
|---|---|---|
| Drug Class | ACE inhibitor (lysine analog, direct) | ACE inhibitor (prodrug → enalaprilat) |
| Nutrients Depleted | 1 — zinc | 1 — zinc |
| Half-Life | 30 hours (once daily) | 12.5 hours (twice daily) |
| Bioavailability | 25% | 40% |
| Hepatic Activation | None required | Required (prodrug) |
| FAERS Reports | 181,237 total | 21,226 total |
| IV Formulation | Not available | Available (enalaprilat) |
| Zinc Depletion Pattern | Continuous (30h sustained) | Cyclical (12.5h per dose) |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both ACE inhibitors deplete only zinc — the lightest nutrient depletion burden of any major antihypertensive class. The choice between them comes down to convenience versus flexibility. Lisinopril's 30-hour half-life delivers once-daily simplicity and no liver dependency, but creates continuous zinc excretion. Enalapril's 12.5-hour half-life may allow intermittent zinc recovery between twice-daily doses, backed by CONSENSUS and SOLVD landmark heart failure trials. According to FAERS analysis of 202,463 combined reports, lisinopril has far more reports (181,237 vs 21,226), reflecting its position as the most-prescribed ACE inhibitor globally. For most hypertension patients, lisinopril's once-daily convenience wins. For heart failure patients specifically, enalapril's landmark trial pedigree gives it evidence-based standing. Either way, zinc picolinate 15–30 mg daily is a simple, inexpensive supplement that fully addresses the single-nutrient depletion burden.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): gene interactions for both drugs affecting ACE pathway, bradykinin metabolism, and zinc homeostasis
- [2]FAERS (FDA Adverse Event Reporting System): 181,237 lisinopril reports; 21,226 enalapril reports
- [3]CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429-1435
- [4]SOLVD Investigators. Effect of enalapril on survival in patients with reduced LVEF and CHF. N Engl J Med. 1991;325(5):293-302
- [5]PubMed PMID 19398235 — Golik A et al. Effects of captopril and enalapril on zinc metabolism in hypertensive patients. J Am Coll Nutr. 1998;17(1):75-78
Check your medications
Check Free →